Mode
Text Size
Log in / Sign up

Probiotics modestly reduce pain intensity and weekly episodes in children with abdominal pain disordersProbiotics may offer modest relief for children with abdominal pain

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider probiotics as a safe adjunctive therapy for pediatric abdominal pain disorders to achieve modest symptom relief.

This systematic review and meta-analysis evaluated the efficacy and safety of probiotic supplementation compared with placebo in 1899 children and adolescents with abdominal pain-related disorders of gut-brain interaction (AP-DGBIs). The analysis focused on conditions including irritable bowel syndrome, functional abdominal pain disorders, and functional dyspepsia.

The authors synthesized evidence showing that probiotics modestly reduced both pain intensity and the number of weekly pain episodes compared to placebo. Regarding complete symptom resolution, the study reported an increased rate with probiotics (35.3%) compared to placebo (22.8%), corresponding to an NNT of 7 (95%CI = 3.97-29.04). However, probiotic supplementation was not associated with different response rates when success was defined by an author-defined threshold.

The authors noted substantial heterogeneity across the included studies and characterized the certainty of evidence as low to moderate across outcomes. Probiotics were considered a safe adjunctive therapy but may not be sufficient as a stand-alone treatment for these conditions. Clinical application should account for the modest nature of the observed effects and the limitations in evidence certainty.

How this fits prior evidence

This finding addresses a gap in managing pediatric functional abdominal pain disorders by evaluating probiotic interventions. While previous coverage noted that Mediterranean-based diets may offer superior efficacy over traditional advice for irritable bowel syndrome, this meta-analysis provides specific data on probiotics as an adjunctive therapy. It also aligns with the broader context of gut microbiota interventions, which have been shown to influence various systems including bone metabolism.

Living with chronic stomach pain is incredibly difficult for children. For those with conditions like irritable bowel syndrome or functional dyspepsia, every meal or daily activity can be a source of discomfort. Researchers looked at how probiotic supplements might help these young patients manage their symptoms.

The review of 1,899 children and adolescents found that probiotics could modestly reduce the intensity of pain and the number of weekly pain episodes. More importantly, children taking probiotics had a higher rate of complete symptom resolution compared to those taking a placebo. While it did not change overall response rates based on specific set thresholds, the results suggest a positive trend for daily comfort.

It is important to note that the evidence for these findings is currently low to moderate because the studies involved were quite different from one another. Because of this uncertainty, doctors view probiotics as a safe addition to current treatments rather than a standalone cure. Talk to a healthcare provider to see if this approach fits your child's specific needs.

What this means for you:
Probiotics may safely help reduce pain intensity and frequency in children with certain gut-related disorders.

Common questions

Can probiotics help my child's stomach pain?

Yes, the study found that probiotic supplements may modestly reduce both the intensity of pain and the number of weekly pain episodes in children with abdominal pain-related disorders. While it is not a standalone treatment, it is considered a safe addition to current care plans.

What are the risks of using probiotics for these conditions?

The research indicates that probiotic supplementation is considered a safe adjunctive therapy for children and adolescents. No serious adverse events or specific safety concerns were reported in the data provided, making it a manageable option to discuss with a doctor.

How effective are probiotics compared to a placebo?

Children taking probiotics showed an increased rate of complete symptom resolution (35.3%) compared to those taking a placebo (22.8%). However, the study did not find a significant difference in response rates when using specific author-defined thresholds.

Study Details

Study typeSystematic review
Sample sizen = 1,899
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
UNLABELLED: Functional abdominal pain disorders (FAPDs), currently referred to as abdominal pain-related disorders of gut-brain interaction (AP-DGBIs), are characterized by recurrent abdominal discomfort in children that cannot be fully explained by an identifiable organic disorder. Probiotics are increasingly used as microbiota-targeted treatments, although their true clinical benefit remains uncertain. The objective of this study is to evaluate the efficacy and safety of probiotic supplementation compared with placebo in children with AP-DGBIs. PubMed, Embase, Web of Science and Scopus were searched from the start of each database to April 2026; the review followed PRISMA guidelines. Randomized controlled trials in patients < 18 years with FAPDs (IBS, FAP-NOS, functional dyspepsia, abdominal migraine) diagnosed by Rome II-IV, in which probiotic supplementation was evaluated. Two reviewers independently extracted data and assessed risk of bias using RoB2 tool. Meta-analyses and network meta-analyses were used to synthesize the data; the certainty of the evidence was evaluated using GRADE and CINeMA. This review covers 21 trials (2005-2025) with 1899 patients treatments completed. Probiotics modestly reduced pain intensity and weekly pain episodes, and modestly increased the rate of complete symptom resolution compared with placebo. Treatment with probiotics was associated with complete symptom resolution in 35.3% versus 22.8% of placebo-treated patients, corresponding to a number needed to treat (NNT) of 7 (95%CI = 3.97-29.04). However, the certainty of evidence was rated as low to moderate across outcomes. Moreover, from a clinical perspective, when success was defined as an improvement in symptoms according to an author-defined threshold, probiotic supplementation was not associated with different response rates compared with placebo. CONCLUSION: Probiotics provide modest symptom relief in pediatric FAPDs and may be considered a safe adjunctive therapy rather than a stand-alone treatment. While these findings are in line with the ESPGHAN/NASPGHAN 2025 guidelines, larger standardized trials are required to define optimal strain selection, dosage and treatment duration. TRIAL REGISTRATION:   https://www.crd.york.ac.uk/PROSPERO/view/CRD420251149947 , identifier CRD420251149947. WHAT IS KNOWN: • AP-DGBIs (formerly FAPDs) are common childhood disorders characterized by recurrent abdominal pain without identifiable organic disease. • Probiotics are increasingly used to restore gut microbial balance, but their clinical benefit remains uncertain. WHAT IS NEW: • Our meta-analysis showed that probiotic supplementation reduced pain intensity and weekly pain episodes and increased symptom resolution versus placebo. • Benefi ts were modest, with substantial heterogeneity across studies and low-to-moderate certainty of evidence.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.